A total of 47 (38.2%) out of 123 patients showed mutations in the RAS pathway (NRAS, KRAS, PTPN11, FLT3, and NF1 in order), which is the most commonly involved pathway in BCP-ALL. The gene discussed is KRAS; the disease is acute lymphoblastic leukemia.